1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Movement Disorders

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Movement Disorders in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alp, MS; Aspey, BS; Harrison, MJ; Patel, Y	1

Reviews

1 review(s) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Movement Disorders

Article	Year
Effects of combined glutamate and platelet-activating factor inhibition on the outcome of focal cerebral ischaemia - an initial screening study. Metabolic brain disease, 1997, Volume: 12, Issue:3 Topics: Animals; Brain Ischemia; Cerebral Infarction; Drug Combinations; Glutamic Acid; Leucine; Male; Movement Disorders; Neuroprotective Agents; Periaqueductal Gray; Piperazines; Platelet Activating Factor; Platelet Membrane Glycoproteins; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Sodium Channel Blockers; Time Factors	1997

Article

Year

Effects of combined glutamate and platelet-activating factor inhibition on the outcome of focal cerebral ischaemia - an initial screening study.

Metabolic brain disease, 1997, Volume: 12, Issue:3

Topics: Animals; Brain Ischemia; Cerebral Infarction; Drug Combinations; Glutamic Acid; Leucine; Male; Movement Disorders; Neuroprotective Agents; Periaqueductal Gray; Piperazines; Platelet Activating Factor; Platelet Membrane Glycoproteins; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Sodium Channel Blockers; Time Factors

1997